PDF (Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB | |
PDF (Supplementary figure)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
807kB |
Item Type: | Article |
---|---|
Title: | Full-length dysferlin transfer by the hyperactive Sleeping Beauty transposase restores dysferlin-deficient muscle |
Creators Name: | Escobar, H., Schöwel, V., Spuler, S., Marg, A. and Izsvák, Z. |
Abstract: | Dysferlin-deficient muscular dystrophy is a progressive disease characterized by muscle weakness and wasting for which there is no treatment. It is caused by mutations in DYSF, a large, multiexonic gene that forms a coding sequence of 6.2 kb. Sleeping Beauty (SB) transposon is a nonviral gene transfer vector, already used in clinical trials. The hyperactive SB system consists of a transposon DNA sequence and a transposase protein, SB100X, that can integrate DNA over 10 kb into the target genome. We constructed an SB transposon-based vector to deliver full-length human DYSF cDNA into dysferlin-deficient H2K A/J myoblasts. We demonstrate proper dysferlin expression as well as highly efficient engraftment (>1,100 donor-derived fibers) of the engineered myoblasts in the skeletal muscle of dysferlin- and immunodeficient B6.Cg-Dysf(prmd) Prkdc(scid)/J (Scid/BLA/J) mice. Nonviral gene delivery of full-length human dysferlin into muscle cells, along with a successful and efficient transplantation into skeletal muscle are important advances towards successful gene therapy of dysferlin-deficient muscular dystrophy. |
Keywords: | Dysferlin, Gene Therapy, Myoblast Transplantation, Sleeping Beauty Transposon, Animals, Mice |
Source: | Molecular Therapy - Nucleic Acids |
ISSN: | 2162-2531 |
Publisher: | Nature Publishing Group |
Volume: | 5 |
Page Range: | e277 |
Date: | 19 January 2016 |
Official Publication: | https://doi.org/10.1038/mtna.2015.52 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page